JP2014527400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527400A5 JP2014527400A5 JP2014517664A JP2014517664A JP2014527400A5 JP 2014527400 A5 JP2014527400 A5 JP 2014527400A5 JP 2014517664 A JP2014517664 A JP 2014517664A JP 2014517664 A JP2014517664 A JP 2014517664A JP 2014527400 A5 JP2014527400 A5 JP 2014527400A5
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- apociii
- population
- secreting cells
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161501480P | 2011-06-27 | 2011-06-27 | |
| US61/501,480 | 2011-06-27 | ||
| PCT/EP2012/062371 WO2013000920A2 (en) | 2011-06-27 | 2012-06-26 | Methods for treating and/or limiting development of diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014527400A JP2014527400A (ja) | 2014-10-16 |
| JP2014527400A5 true JP2014527400A5 (cg-RX-API-DMAC7.html) | 2015-06-11 |
| JP6242790B2 JP6242790B2 (ja) | 2017-12-06 |
Family
ID=46331358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517664A Expired - Fee Related JP6242790B2 (ja) | 2011-06-27 | 2012-06-26 | 糖尿病の治療および／または発症抑制を行うための候補化合物を同定する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US8557513B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2724155B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6242790B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101937260B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103620404B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013000920A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8557513B2 (en) * | 2011-06-27 | 2013-10-15 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
| PL2936151T3 (pl) | 2012-12-18 | 2018-11-30 | Biocrine Ab | Sposoby leczenia i/lub ograniczania rozwoju cukrzycy |
| JP2014161257A (ja) * | 2013-02-22 | 2014-09-08 | Univ Of Tokyo | 多能性幹細胞から膵ランゲルハンス島を製造する方法 |
| WO2014131008A1 (en) | 2013-02-25 | 2014-08-28 | Intrinsic Metabio Solutions, Llc | A polipoprotein c3 (apociii) antagonists and methods of their use to remove apociii inhibition of lipoprotein lipase (lpl) |
| DK2970463T3 (en) * | 2013-03-13 | 2018-01-22 | Biocrine Ab | METHOD OF TREATING AND / OR LIMITING THE DEVELOPMENT OF DIABETES |
| KR20150046852A (ko) * | 2013-10-23 | 2015-05-04 | 삼성전자주식회사 | 전자 장치 및 전자 장치의 암호를 이용한 인증 방법 |
| KR102206054B1 (ko) * | 2014-05-09 | 2021-01-21 | 삼성전자주식회사 | 지문 처리 방법 및 그 전자 장치 |
| US9474951B2 (en) * | 2015-01-21 | 2016-10-25 | William Chuang | Golf tee structures, assemblies, and systems with improved accuracy |
| JP6655080B2 (ja) | 2015-02-09 | 2020-02-26 | ビオクリネ エービー | 筋萎縮性側索硬化症を有する対象における糖尿病を治療する方法および／または糖尿病の発症を制限する方法 |
| JP7341916B2 (ja) * | 2015-04-01 | 2023-09-11 | ビーエーエスエフ エーエス | アポｃ３を低下させるためのチアオキソ化合物の使用 |
| CA3030099A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| CN111315772A (zh) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | 抗apoc3抗体及其使用方法 |
| EP3823648B1 (en) | 2018-07-19 | 2023-06-07 | BioCrine AB | Methods for treating diabetes |
| US11310268B2 (en) | 2019-05-06 | 2022-04-19 | Secureworks Corp. | Systems and methods using computer vision and machine learning for detection of malicious actions |
| US11381589B2 (en) | 2019-10-11 | 2022-07-05 | Secureworks Corp. | Systems and methods for distributed extended common vulnerabilities and exposures data management |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492325B1 (en) * | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
| US20030083242A1 (en) * | 1998-11-06 | 2003-05-01 | Alphonse Galdes | Methods and compositions for treating or preventing peripheral neuropathies |
| ATE553782T1 (de) * | 1999-12-22 | 2012-05-15 | Scripps Research Inst | Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung |
| CA2453403C (en) * | 2001-07-09 | 2013-10-08 | Elan Pharmaceuticals, Inc. | Methods of inhibiting amyloid toxicity |
| US9062306B2 (en) | 2003-04-29 | 2015-06-23 | Biocrine Ab | Methods for identifying compounds for treating type 1 diabetes |
| US20060094682A1 (en) * | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
| JP2008538812A (ja) * | 2005-04-11 | 2008-11-06 | アストラゼネカ アクチボラグ | 方法 |
| US20090060843A1 (en) | 2007-08-31 | 2009-03-05 | Biocrine Ab | Non-Invasive In Vivo Imaging and Methods for Treating Type I Diabetes |
| US20110008901A1 (en) * | 2009-07-07 | 2011-01-13 | Kiernan Urban A | Apolipoprotein ciii in pre- and type 2 diabetes |
| US8557513B2 (en) * | 2011-06-27 | 2013-10-15 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
-
2012
- 2012-06-25 US US13/532,601 patent/US8557513B2/en not_active Expired - Fee Related
- 2012-06-26 EP EP12729166.4A patent/EP2724155B1/en active Active
- 2012-06-26 JP JP2014517664A patent/JP6242790B2/ja not_active Expired - Fee Related
- 2012-06-26 WO PCT/EP2012/062371 patent/WO2013000920A2/en not_active Ceased
- 2012-06-26 CN CN201280028829.1A patent/CN103620404B/zh not_active Expired - Fee Related
- 2012-06-26 KR KR1020147000028A patent/KR101937260B1/ko not_active Expired - Fee Related
-
2013
- 2013-09-13 US US14/026,145 patent/US9068973B2/en active Active
-
2015
- 2015-05-20 US US14/717,903 patent/US9353183B2/en active Active
-
2016
- 2016-01-14 US US14/995,645 patent/US20160194634A1/en not_active Abandoned
- 2016-01-14 US US14/995,341 patent/US9744232B2/en active Active
-
2017
- 2017-07-26 US US15/660,340 patent/US10226530B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527400A5 (cg-RX-API-DMAC7.html) | ||
| Takahashi et al. | Cancer cells co-opt the neuronal redox-sensing channel TRPA1 to promote oxidative-stress tolerance | |
| Bhattacharyya et al. | FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling | |
| Salpeter et al. | Systemic regulation of the age-related decline of pancreatic β-cell replication | |
| Xiao et al. | EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis | |
| Zheng et al. | The coordinated roles of miR-26a and miR-30c in regulating TGFβ1-induced epithelial-to-mesenchymal transition in diabetic nephropathy | |
| Varga et al. | Antitransforming growth factor-β therapy in fibrosis: recent progress and implications for systemic sclerosis | |
| Lorenzen et al. | Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis | |
| Chau et al. | MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways | |
| Alimonti et al. | A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis | |
| Febbraro et al. | α-Synuclein expression is modulated at the translational level by iron | |
| Omote et al. | Role of the TNF pathway in the progression of diabetic nephropathy in KK-Ay mice | |
| Sotgia et al. | Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms | |
| Bodempudi et al. | miR-210 promotes IPF fibroblast proliferation in response to hypoxia | |
| Zhou et al. | Wnt/β-catenin signaling and renin–angiotensin system in chronic kidney disease | |
| Andres et al. | Deletion of intestinal epithelial insulin receptor attenuates high-fat diet-induced elevations in cholesterol and stem, enteroendocrine, and Paneth cell mRNAs | |
| Porteiro et al. | Hepatic p63 regulates steatosis via IKKβ/ER stress | |
| O’Reilly et al. | Senescence and tissue fibrosis: Opportunities for therapeutic targeting | |
| WO2013000920A3 (en) | Methods for identifying candidate compounds for treating and/or limiting development of diabetes | |
| Sayar et al. | EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non‐linear, V‐shaped relationship | |
| Cannatà et al. | Pathways for salvage and protection of the heart under stress: novel routes for cardiac rejuvenation | |
| Saito et al. | Mechanism of impairment on liver regeneration in elderly patients: role of hepatic stellate cell function | |
| Koga et al. | The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice | |
| Siddiqi et al. | Cardiac hegemony of senescence | |
| Schirmer et al. | Preoperative administration of angiotensin-converting enzyme inhibitors |